Report

reporttype1receiptdateformat102companynumbUS-JNJFOC-20140215653occurcountryUSVersion of Safety Report ID3receivedateformat102duplicate1transmissiondateformat102fulfillexpeditecriteria1Safety Report ID10039702Date Received26/03/2014transmissiondate12/12/2014serious2Date Last Updated27/05/2014primarysourcecountryUS

Receiver

receivertype6receiverorganizationFDA

Primary Source

reportercountryUSqualification2

Sender

sendertype2senderorganizationFDA-Public Use

Patient

Onset Age45Unit of Onset AgeyearsSexMale

Reaction

1)

reactionmeddraversionpt17.0ReactionIncorrect route of drug administrationOutcomeUnknown

2)

reactionmeddraversionpt17.0ReactionParaesthesiaOutcomeNot recovered/not resolved

3)

reactionmeddraversionpt17.0ReactionMuscular weaknessOutcomeNot recovered/not resolved

Drug

1)

drugcharacterization1medicinalproductINVEGA SUSTENNAdrugauthorizationnumb022264drugstructuredosagenumb234drugstructuredosageunit003drugdosageformINJECTIONdrugadministrationroute030drugindicationPRODUCT USED FOR UNKNOWN INDICATIONdrugstartdateformat102drugstartdate12/07/2013actiondrug4drugrecurreadministration2

openFDA Info on Medication

Application NumberNDA022264Brand NameINVEGA SUSTENNAGeneric NamePALIPERIDONE PALMITATEManufacturersJanssen Pharmaceuticals, Inc.product_ndc50458-560, 50458-561, 50458-562, 50458-563, 50458-564Product TypeHUMAN PRESCRIPTION DRUGRouteINTRAMUSCULARActive IngredientsPALIPERIDONE PALMITATERXCUI858048, 858051, 858052, 858053, 858054, 858055, 858056, 858057, 858073, 858074spl_idd76b9144-d2d3-4d6d-89cd-bb86b89b1ceaspl_set_id1af14e42-951d-414d-8564-5d5fce138554Package NDC 50458-560-01, 50458-561-01, 50458-562-01, 50458-563-01, 50458-563-03, 50458-564- ... UNIIR8P8USM8FR

2)

drugcharacterization2medicinalproductLIPITORdrugstructuredosagenumb40drugstructuredosageunit003drugdosageformUnspecifieddrugadministrationroute065

openFDA Info on Medication

Application NumberNDA020702Brand NameLIPITORGeneric NameATORVASTATIN CALCIUMManufacturersParke-Davis Div of Pfizer Incproduct_ndc0071-0155, 0071-0156, 0071-0157, 0071-0158Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsATORVASTATIN CALCIUM TRIHYDRATERXCUI259255, 262095, 617310, 617311, 617312, 617314, 617318, 617320spl_id0ba214c6-250e-42a0-aea8-5e44aba04882spl_set_idc6e131fe-e7df-4876-83f7-9156fc4e8228Package NDC 0071-0155-23, 0071-0155-40, 0071-0155-10, 0071-0155-97, 0071-0156-23, 0071-0156- ... UNII48A5M73Z4Q

3)

drugcharacterization2medicinalproductBENZTROPINEdrugstructuredosagenumb2drugstructuredosageunit003drugdosageformUnspecifieddrugadministrationroute065

openFDA Info on Medication

Application NumberANDA090294Brand NameBENZTROPINE MESYLATEGeneric NameBENZTROPINEManufacturersCipla USA Inc.product_ndc69097-826, 69097-827, 69097-832Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsBENZTROPINE MESYLATERXCUI885209, 885213, 885219spl_id3d362141-de53-4949-b9a5-34f2b7bb0e75spl_set_id3d2732f9-b8a9-4e83-91e7-da616ddcb786Package NDC 69097-826-02, 69097-826-07, 69097-826-15, 69097-827-02, 69097-827-07, 69097-827- ... UNIIWMJ8TL7510

4)

drugcharacterization2medicinalproductZYRTECdrugstructuredosagenumb20drugstructuredosageunit003drugdosageformUnspecifieddrugadministrationroute048

openFDA Info on Medication

Application NumberNDA022429Brand NameZYRTECGeneric NameCETIRIZINE HYDROCHLORIDEManufacturersJohnson & Johnson Consumer Inc., McNeil Consumer Healthcare Divisionproduct_ndc50580-779Product TypeHUMAN OTC DRUGRouteORALActive IngredientsCETIRIZINE HYDROCHLORIDERXCUI1014675, 1020023spl_idd7532844-79d8-4648-ab9b-e5d3d3ad76f9spl_set_id605adf29-734f-451a-8ff3-74be7b5814a6Package NDC50580-779-12, 50580-779-25, 50580-779-40, 50580-779-65UNII64O047KTOA

5)

drugcharacterization2medicinalproductDEPAKOTEdrugdosagetext2000MG/100MGdrugdosageformUnspecifieddrugadministrationroute048

openFDA Info on Medication

Application NumberNDA021168, NDA018723, NDA019680Brand NameDEPAKOTE ER, DEPAKOTE, DEPAKOTE SPRINKLESGeneric NameDIVALPROEX SODIUMManufacturersAbbVie Inc.product_ndc0074-3826, 0074-7126, 0074-6212, 0074-6214, 0074-6215, 0074-6114Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsDIVALPROEX SODIUMspl_id 94344b70-6db3-4dd1-891a-16ccf096a3eb, bb31c7ee-b0a3-42ab-a6b3-b27b3441db1e, 9aef ... spl_set_id 0dc024ce-efc8-4690-7cb5-639c728fccac, 08a65cf4-7749-4ceb-6895-8f4805e2b01f, 4619 ... Package NDC 0074-3826-11, 0074-3826-13, 0074-7126-11, 0074-7126-72, 0074-7126-13, 0074-7126- ... UNII644VL95AO6

6)

drugcharacterization2medicinalproductSINGULAIRdrugstructuredosagenumb10drugstructuredosageunit003drugdosageformUnspecifieddrugadministrationroute065

openFDA Info on Medication

Application NumberNDA020829, NDA020830, NDA021409Brand NameSINGULAIRGeneric NameMONTELUKAST SODIUMManufacturersMerck Sharp & Dohme Corp.product_ndc0006-9117, 0006-3841, 0006-1711, 0006-9275Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsMONTELUKAST SODIUMRXCUI153892, 153893, 200224, 242438, 261367, 311759, 351246, 404406spl_id96717981-6ea2-4720-a749-e14f1559511fspl_set_id8c166755-7711-4df9-d689-8836a1a70885Package NDC 0006-3841-30, 0006-3841-14, 0006-1711-31, 0006-1711-54, 0006-9275-31, 0006-9275- ... UNIIU1O3J18SFL

7)

drugcharacterization2medicinalproductPROTONIXdrugstructuredosagenumb40drugstructuredosageunit003drugdosageformUnspecifieddrugadministrationroute065

openFDA Info on Medication

Application NumberNDA020988, NDA020987, NDA022020Brand NamePROTONIX I.V., PROTONIX DELAYED-RELEASEGeneric NamePANTOPRAZOLE SODIUMManufacturersWyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.product_ndc0008-0923, 0008-2001, 0008-4001, 0008-0841, 0008-0843, 0008-0844Product TypeHUMAN PRESCRIPTION DRUGRouteINTRAVENOUS, ORALActive IngredientsPANTOPRAZOLE SODIUMRXCUI283669, 885257, 251872, 284400, 314200, 352125, 763306, 763308spl_id b326d5db-8b20-4ec4-ac25-78190fb3ac36, 1e8fa399-506d-4bcd-9097-dbf7850147bf, 7bdf ... spl_set_id 51e4144a-489e-436c-609a-39305f8f56ba, 5b5ddedd-d429-41a7-8573-10c3e9ad4e52, f39b ... Package NDC 0008-0923-51, 0008-0923-60, 0008-0923-55, 0008-2001-01, 0008-2001-25, 0008-2001- ... UNII6871619Q5X

8)

drugcharacterization2medicinalproductPROPRANOLOLdrugdosagetext20MG/10MGdrugdosageformUnspecifieddrugadministrationroute065

openFDA Info on Medication

Application NumberANDA075826Brand NamePROPRANOLOLGeneric NamePROPRANOLOL HYDROCHLORIDEManufacturersFresenius Kabi USA, LLCproduct_ndc63323-604Product TypeHUMAN PRESCRIPTION DRUGRouteINTRAVENOUSActive IngredientsPROPRANOLOL HYDROCHLORIDERXCUI856443spl_iddb24d808-268b-4bec-bd48-7b66d2bb5951spl_set_idf14ea537-dd5c-4c78-9037-9a85e9e610efPackage NDC63323-604-01UNIIF8A3652H1V

9)

drugcharacterization2medicinalproductZOLOFTdrugstructuredosagenumb200drugstructuredosageunit003drugdosageformUnspecifieddrugadministrationroute065

openFDA Info on Medication

Application NumberNDA020990, NDA019839Brand NameZOLOFTGeneric NameSERTRALINE HYDROCHLORIDEManufacturersRoerigproduct_ndc0049-0050, 0049-4960, 0049-4900, 0049-4910Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsSERTRALINE HYDROCHLORIDERXCUI208149, 208161, 212233, 312938, 312940, 312941, 861064, 861066spl_id665a145d-44fb-4fef-a3c1-2aac26e0715cspl_set_idfe9e8b7d-61ea-409d-84aa-3ebd79a046b5Package NDC 0049-4960-30, 0049-4960-50, 0049-4900-30, 0049-4900-66, 0049-4900-73, 0049-4900- ... UNIIUTI8907Y6X

10)

drugcharacterization2medicinalproductTRAZODONEdrugstructuredosagenumb50drugstructuredosageunit003drugseparatedosagenumb1drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosageformUnspecifieddrugadministrationroute065

11)

drugcharacterization2medicinalproductVITAMIN B3drugstructuredosagenumb400drugstructuredosageunit003drugdosageformUnspecifieddrugadministrationroute065

Report Duplicate

duplicatesourceJANSSENduplicatenumbUS-JNJFOC-20140215653

Adverse Event Report

Report

Receiver

Primary Source

Sender

Patient

Reaction

1)

2)

3)

Drug

1)

openFDA Info on Medication

2)

openFDA Info on Medication

3)

openFDA Info on Medication

4)

openFDA Info on Medication

5)

openFDA Info on Medication

6)

openFDA Info on Medication

7)

openFDA Info on Medication

8)

openFDA Info on Medication

9)

openFDA Info on Medication

10)

11)

Report Duplicate

Media

Newsletter

Follow us

Connect with us